GAMCO Investors’s AstraZeneca AZN Stock Holding History

GAMCO Investors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-3,160	Closed	-$428K	–	879
2022 Q4	$428K	Buy	3,160 +127	+4%	+$15.9K	﹤0.01%	713
2022 Q3	$375K	Sell	3,033 -2,102	-41%	-$267K	﹤0.01%	721
2022 Q2	$679K	Sell	5,135 -15	-0.3%	-$1.97K	0.01%	648
2022 Q1	$683K	Buy	5,150 +150	+3%	+$18K	0.01%	683
2021 Q4	$583K	Sell	5,000 -2,275	-31%	-$268K	0.01%	711
2021 Q3	$874K	Buy	+7,275	New	+$847K	0.01%	652
2015 Q3	–	Sell	-4,200	Closed	-$268K	–	832
2015 Q2	$268K	Sell	4,200 -7,600	-64%	-$520K	﹤0.01%	762
2015 Q1	$807K	Sell	11,800 -8,100	-41%	-$563K	﹤0.01%	656
2014 Q4	$1.4M	Sell	19,900 -22,000	-53%	-$1.58M	0.01%	596
2014 Q3	$2.99M	Buy	41,900 +1,500	+4%	+$110K	0.02%	480
2014 Q2	$3M	Buy	+40,400	New	+$2.92M	0.02%	478

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

GAMCO Investors's AZN Position: Q1 2023 in Review

GAMCO Investors sold out of AstraZeneca (AZN) in Q1 2023, closing a stake of 3,160 shares — an estimated $428K sold.

GAMCO Investors first reported a position in AZN in Q2 2014 and held it in 11 quarters. The position peaked at $3M in Q2 2014. 1,054 funds tracked by Wall St. Rank hold AZN as of Q1 2023.

GAMCO Investors reported no remaining AstraZeneca position as of Q1 2023 after selling out during the quarter.
GAMCO Investors sold 3,160 AstraZeneca shares in Q1 2023, an estimated $428K.
GAMCO Investors first reported a position in AstraZeneca in Q2 2014 and held it in 11 quarters.
GAMCO Investors's AstraZeneca position peaked at $3M in Q2 2014.
1,054 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2023.

Based on GAMCO Investors's 13F filing for Q1 2023, filed 12 May 2023.